MedTrace Logo

Intra-articular Injection of Allogeneic Platelet Rich Plasma (PRP) for Adhesive Capsulitis

NCT01458691 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2020-10-08

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy of intra-articular allogenic Platelet Rich Plasma injection and steroid injection in the treatment of adhesive capsulitis of the shoulder.

Conditions

  • Adhesive Capsulitis

Interventions

PROCEDURE

Steroid injection into the glenohumeral joint

* Group: Steroid * Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine) * The number of injections : only once during the study period * Injection site : glenohumeral joint * Material : 25-gauze spinal needle * The intra-articular injections were performed using ultrasonographic guidance.

PROCEDURE

Allogeneic PRP injection into the glenohumeral joint

* Group: Allogeneic PRP * Total volume of injection drugs: 4ml * The number of injections : only once during the study period * Injection site : glenohumeral joint * Material : 25-gauze spinal needle * The intra-articular injections were performed using ultrasonographic guidance.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Chris H. Jo, M.D., Ph.D · Joint & Spine Center, SMG-SNU Boramae Medical Center, Department of Orthopedic Surgery, Seoul National University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2015-03-31
Completion
2015-10-20

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01458691 on ClinicalTrials.gov